Bioinformatics analysis shows association between a gene expression signature and biochemical relapse after radical prostatectomy in patients with prostate cancer.

ABBATE MERCEDES; COTIGNOLA, JAVIER; BIZZOTTO JUAN; ELBA VAZQUEZ; BRANDANI JAVIER; GERALDINE GUERON

Mar del Plata

Congreso; Sociedad Argentina de Investigacion Clinica; 2018

Prostate cancer (PCa) is the second most incident type of cancer in men and the fifth leading cause of cancer-related deaths worldwide. Surgical resection of the entire gland by radical prostatectomy is one therapeutic option with curative purposes for men with organ confined PCa. However, 30?40% of patients will have a biochemical relapse (BCR) after surgery, which may indicate clinical recurrence of an aggressive disease. Current clinical indicators of PCa recurrence after radical prostatectomy have limited sensitivity and specificity. Thus, the ability to establish the risk of progression after surgery is of high importance for patient management and to avoid overtreatment. We used transcriptome data from the dataset GSE54460 publicly available at GEO-NCBI to study differential gene expression between patients with and without BCR post radical prostatectomy. We obtained a list of 1021 genes differentially expressed (adjusted p40% of the subsamples. The selected genes were: CRISP3, APOE, CEL and DDTL; and they all were significantly overexpressed in the tumors of patients who relapsed. The analysis of BCR-free survival showed significant poorer survival for patients with high-tumoral expression of these genes. Moreover, the risk of BCR is >2-fold for patients with high-tumoral expression compared to patients with low expression. The analysis of the combined expression showed a HR=15 (95%CI=3.5-63.9) for patients with high-tumoral expression for two or more genes. In conclusion, the expression signature of these genes might have the potential to detect aggressive tumors and predict BCR at the time of radical prostatectomy.